News >

Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC

Danielle Bucco
Published: Friday, Apr 13, 2018

Mark J. Mann, MD

Mark J. Mann, MD
There have not been designated novel treatment options for patients with nonmetastatic castration-resistant prostate cancer (CRPC) until very recently, explains Mark J. Mann, MD.

State of the Science Summit™ on Prostate Cancer, Mann, an assistant professor of urology at Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discussed the developing treatment landscape for patients with nonmetastatic CRPC.

OncLive®: Please provide an overview of your lecture on the treatment of nonmetastatic CRPC.

Mann: The definition of nonmetastatic CRPC is a patient with a prostate-specific antigen (PSA) that is 2 over the nadir, or a 25% increase from the nadir while the testosterone is still repressed. The next part of the diagnosis is determining whether it is metastatic. That is done with a CT scan and a bone scan, which are standard, but there are new imaging modalities that are starting to come into play, specifically PET scans.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication